J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
In J-TAIL-2, atezolizumab plus CE had efficacy in patients with ES-SCLC in clinical practice that was consistent with that in IMpower133. Taken together with the acceptable safety profile, these data support the use of atezolizumab plus CE in patients with ES-SCLC in Japan, including those who would have been ineligible for IMpower133.
Authors
- Kadoaki Ohashi (ORCID: https://orcid.org/0000-0002-5180-3933)
- Akihiko Gemma (ORCID: https://orcid.org/0000-0003-0762-2737)
- Eisaku Miyauchi (ORCID: https://orcid.org/0000-0002-6837-6392)
- Takashi Kijima (ORCID: https://orcid.org/0000-0003-4249-4021)
- Junichi Shimizu (ORCID: https://orcid.org/0000-0001-9078-0968)
- Toshihiro Misumi (ORCID: https://orcid.org/0000-0001-8339-2895)
- Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
- Hiroshige Yoshioka (ORCID: https://orcid.org/0000-0001-7724-0481)
- Atsushi Osoegawa (ORCID: https://orcid.org/0000-0002-8327-3631)
- Yasushi Goto
- Eiki Kikuchi (ORCID: https://orcid.org/0000-0003-4098-6321)
- Masahide Oki (ORCID: https://orcid.org/0000-0001-6302-4534)
- Hideharu Kimura
- Ichiro Yoshino (ORCID: https://orcid.org/0009-0003-4007-9606)
- Kenichi Chikamori
- Nobuyuki Katakami
- Misa Tanaka
- Asako Miwa
- Yuki Kobayashi
- Makoto Nishio
Institutions
- Kansai Medical University (JP)
- Oita University (JP)
- Hokkaido University (JP)
- Tohoku University Hospital (JP)
- Okayama University Hospital (JP)
- Kanazawa University Hospital (JP)
- Aichi Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Osaka International Cancer Institute (JP)
- Nagoya Medical Center (JP)
- Takarazuka City Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- International University of Health and Welfare (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100783
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Taiho Pharmaceutical
- Boehringer Ingelheim Japan
- Nipro
- Eisai
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Novartis Pharma
- Chugai Pharmaceutical
- MSD K.K.
- Eli Lilly Japan
- Sanofi K.K.
- Daiichi Sankyo Europe